Apoptosis as a tool for therapeutic agents in haematological diseases

被引：6

作者：

Alenzi, FQB

Wyse, RKH

Altamimi, WG

机构：

[1] King Faisal Univ, Coll Appl Med Sci, Dept Med Lab Sci, Dammam 31451, Saudi Arabia

[2] Univ London Imperial Coll Sci Technol & Med, Dept Cardiac Surg, London W12 0NN, England

[3] King Fahad Cent Hosp, Dept Pathol & Lab Med, King Abdulaziz Med City, Riyadh 11426, Saudi Arabia

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2004年 / 4卷 / 03期

关键词：

apoptosis; drug development; haematological disease; leukaemia; lymphoma;

D O I：

10.1517/14712598.4.3.407

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Apoptosis, an active mechanism of cell death, is an important process in many biological systems. Apoptosis is thought to contribute to many disease processes. This notion has raised expectations that therapeutic opportunities will naturally follow once a better understanding of these processes has been achieved. The regulation of apoptosis in normal and malignant haematological diseases represents an important theraputic approach in the treatment of leukaemia and lymphoma. This review summarises recent developments in the clinical manipulation of apoptosis pathways in haematological therapy.

引用

收藏

页码：407 / 420

页数：14

相关论文

共 159 条

[1]

AGLIETTA M, 1989, EXP HEMATOL, V17, P296

[2] THE SPECTRUM OF MOLECULAR ALTERATIONS IN THE EVOLUTION OF CHRONIC MYELOCYTIC-LEUKEMIA [J].

AHUJA, H ;

BARELI, M ;

ARLIN, Z ;

ADVANI, S ;

ALLEN, SL ;

GOLDMAN, J ;

SNYDER, D ;

FOTI, A ;

CLINE, M .

JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2042-2047

[3] Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal [J].

Albrecht, T ;

Schwab, R ;

Henkes, M ;

Peschel, C ;

Huber, C ;

Aulitzky, WE .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) :501-507

[4] Cellular and molecular themes in apoptosis [J].

Alenzi, FQB ;

Warrens, AN .

WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (15-16) :563-574

[5] A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics [J].

Alenzi, FQB ;

Marley, SB ;

Lewis, JL ;

Chandrashekran, A ;

Warrens, AN ;

Goldman, JM ;

Gordon, MY .

EXPERIMENTAL HEMATOLOGY, 2002, 30 (12) :1428-1435

[6] Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3 [J].

Amarante-Mendes, GP ;

Kim, CN ;

Liu, L ;

Huang, Y ;

Perkins, CL ;

Green, DR ;

Bhalla, K .

BLOOD, 1998, 91 (05) :1700-1705

[7] APOPTOSIS IN CHRONIC MYELOID-LEUKEMIA - NORMAL RESPONSES BY PROGENITOR CELLS TO GROWTH-FACTOR DEPRIVATION, X-IRRADIATION AND GLUCOCORTICOIDS [J].

AMOS, TAS ;

LEWIS, JL ;

GRAND, FH ;

GOODING, RP ;

GOLDMAN, JM ;

GORDON, MY .

BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :387-393

[8] Death receptors: Signaling and modulation [J].

Ashkenazi, A ;

Dixit, VM .

SCIENCE, 1998, 281 (5381) :1305-1308

[9]

BEDI A, 1994, BLOOD, V83, P2038

[10] BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].

BEDI, A ;

BARBER, JP ;

BEDI, GC ;

ELDEIRY, WS ;

SIDRANSKY, D ;

VALA, MS ;

AKHTAR, AJ ;

HILTON, J ;

JONES, RJ .

BLOOD, 1995, 86 (03) :1148-1158

← 1 2 3 4 5 6 7 8 9 10 →